Drug Patch Approved for Advanced Parkinson's and Restless Leg Syndrome
TUESDAY, April 3 (HealthDay News) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker UCB said Tuesday in a news release.
The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.
The dopamine agonist skin patch is believed to work by stimulating dopamine receptors within the caudate-putamen, the portion of the brain that regulates movement, the company said.
In clinical testing, observed side effects of Neupro included nausea, vomiting, skin site reactions, dizziness, insomnia and headache.
Neupro contains sodium metabisulfite, which could cause deadly allergic-like reactions in certain susceptible people. Also, the drug should not be used by pregnant women, UCB warned.
To learn more about this medication, visit Medline Plus.Related Articles
- FDA Approves First Device to Prevent Migraines
March 11, 2014
- Pfizer Recalls Some Antidepressants After Drug Mixup
March 07, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2012 HealthDay. All rights reserved.